Apoptosis
Experimental model of multiple sclerosis: preclinical evaluation of the PI3K/Akt/mTOR pathway
The PI3K/AKT/mTOR pathway is an intracellular signalling pathway that regulates cell activation, proliferation, metabolism and apoptosis. Increasing body of data...
Combination therapy based on Tafinlar and Mekinist for adjuvant treatment of BRAF V600 mutation-positive melanoma: approved in European Union
The European Commission has approved Tafinlar ( Dabrafenib ) in combination with Mekinist ( Trametinib ) for the adjuvant treatment...
Multiple sclerosis: emerging roles of endothelial cells in pathophysiology and therapy
Multiple sclerosis ( MS ) is increasingly being viewed and studied not only as an immune-mediated demyelinating and neurodegenerative disease...
FDA has granted Priority Review for Venetoclax, an inhibitor of the Bcl-2 protein, in chronic lymphocytic leukemia
The FDA ( Food and Drug Administration ) has accepted the New Drug Application ( NDA ) and granted Priority...
Cardiotoxicity associated with targeted cancer therapies
Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in...
HER2+ breast carcinoma: Lapatinib and Trastuzumab shrinks cancer in 11 days after diagnosis
Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs...
Nonalcoholic steatohepatitis: Selonsertib has shown improvement in fibrosis stage in patients with moderate to severe fibrosis
Detailed results from an open-label phase 2 trial evaluating the investigational apoptosis signal-regulating kinase 1 ( ASK1 ) inhibitor Selonsertib...
Arginine-degrading-enzyme therapy may be a useful strategy for treating bladder cancer lacking the enzyme needed for arginine synthesis
With few treatment options available to patients with advanced bladder cancer, investigators are looking for novel molecular targets. In a...
Neoadjuvant Dasatinib for muscle-invasive bladder cancer: Src inhibition appears ineffective in unselected patients
Preclinical urothelial carcinoma models suggest activity of Dasatinib ( Sprycel ), an oral Src-family kinase ( SFK ) inhibitor. Researchers...
FDA: Darzalex granted Breakthrough Therapy Designation for use in combination with standard of care regimens for patients with multiple myeloma
The FDA ( Food and Drug Administration ) has granted a Breakthrough Therapy Designation to the immunotherapy Darzalex ( Daratumumab...
EGFR mutations in non-small-cell lung carcinoma
EGFR belongs to the ErbB family of transmembrane tyrosine kinase receptors ( ErbB comprises ErbB1/EGFR/HER1, ErbB2/HER2/NEU, ErbB3/HER3, and ErbB4/HER4 )....
Venetoclax in patients with relapsed / refractory or previously untreated chronic lymphocytic leukemia with 17p deletion: phase II trial met primary endpoint
A phase 2 trial of the investigational medicine Venetoclax met its primary endpoint ( overall response rates ) in patients...
HER2-positive breast cancer: PIK3CA mutations as a potential predictive marker of resistance to treatment with Lapatinib and Trastuzumab
The CHER-LOB randomized phase II study showed that the combination of Lapatinib ( Tyverb ) and Trastuzumab ( Herceptin )...
Blinatumomab: positive results in patients with relapsed / refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia
Results of a phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of Blinatumomab ( Blincyto )...
Multiple sclerosis patients: interleukin-22 is increased and targets astrocytes
Increasing evidences link T helper 17 ( Th17 ) cells with multiple sclerosis ( MS ). In this context, interleukin-22...
Acute myeloid leukaemia: efficacy of Volasertib associated with low dose Cytarabine
Acute myeloid leukaemia ( AML ) is an aggressive and devastating blood cancer. It predominantly affects people over 60 and...
Volasertib improves overall survival in older patients with acute myeloid leukaemia
Results from a phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated...
Blincyto, the first-and-only bispecific CD19-directed CD3 T-cell engager immunotherapy for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia
The FDA ( Food and Drug Administration ) has granted approval of Blincyto ( Blinatumomab ) for the treatment of...
lncRNAs in urine and tissue appear to have an important role in prostate cancer diagnostics
Researchers at Sanford-Burnham Medical Research Institute ( Orlando, Florida; United States ) have identified a set of RNA molecules that...
Identification of ruptured and high-risk coronary atherosclerotic plaques: 18F-fluoride positron emission tomography
The use of non-invasive imaging to identify ruptured or high-risk coronary atherosclerotic plaques would represent a major clinical advance for...